SABCS 2022 Conference Coverage


 

SABCS 2022 on a Randomized Phase II PACE (Palbociclib After CDK4/6i & ET) Study: Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-Treated ER+/HER2- mBC

333 views
December 13, 2022
Comments 0
Login to view comments. Click here to Login